Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease

Badri Modi(City Of Hope National Medical Center), Ryotaro Nakamura(City Of Hope National Medical Center), Jonathan Cotliar(Harbor–UCLA Medical Center), Erin Kopp(City of Hope), Sally Mokhtari(City of Hope), Stephen J. Forman(City Of Hope National Medical Center), Sanjeet Dadwal(City Of Hope National Medical Center), Ricardo Spielberger(City of Hope), Monzr M. Al Malki(City of Hope), Karen M. Huelsman(TriHealth), Michael Hernandez-Henderson(Meharry Medical College), Amandeep Salhotra(City of Hope), Haris Ali(City of Hope), Dongyun Yang(City of Hope), Pablo Parker(City Of Hope National Medical Center), Jeremy Klein(City of Hope), Jasmine Zain(City of Hope)
Biology of Blood and Marrow Transplantation
September 8, 2018
10.1016/j.bbmt.2018.09.003
Cited by 84

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k